Compare Stocks → A new way to collect income from stocks (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison TSE:HLSCVE:NXS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHLSHLS TherapeuticsC$4.73-0.4%C$4.29C$3.34▼C$7.12C$150.98M1.169,501 shs4,512 shsNXSNexus GoldC$0.02C$0.02C$0.02▼C$0.10C$628K0.8566,764 shs50,800 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHLSHLS Therapeutics0.00%-2.86%+29.08%+16.14%-20.17%NXSNexus Gold0.00%-25.00%-40.00%0.00%+200.00%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHLSHLS Therapeutics0.0655 of 5 stars1.10.01.70.00.60.80.0NXSNexus GoldN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHLSHLS Therapeutics2.25HoldC$4.58-3.28% DownsideNXSNexus GoldN/AN/AN/AN/ACurrent Analyst RatingsLatest HLS, NXS, and EOF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2024HLSHLS TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetC$6.50 ➝ C$5.003/15/2024HLSHLS TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetC$4.35 ➝ C$4.152/22/2024HLSHLS TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetC$5.00 ➝ C$4.352/6/2024HLSHLS TherapeuticsClarus SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHLSHLS TherapeuticsC$63.07M2.39C$0.31 per share15.22C$3.06 per share1.55NXSNexus GoldN/AN/AC$0.00 per share10.00C($0.01) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHLSHLS Therapeutics-C$27.53M-C$1.16N/A∞N/A-43.65%-24.69%-2.87%5/9/2024 (Estimated)NXSNexus Gold-C$1.92M-C$0.06N/A∞N/AN/A-1,307.50%-53.77%5/29/2024 (Estimated)Latest HLS, NXS, and EOF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023HLSHLS Therapeutics-C$0.13-C$0.18-C$0.05-C$0.13C$21.83 millionC$21.60 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHLSHLS TherapeuticsC$0.204.23%N/AN/A N/ANXSNexus GoldN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHLSHLS Therapeutics89.691.651.01NXSNexus Gold14,120.330.050.38OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHLSHLS Therapeutics59.62%NXSNexus GoldN/AInsider OwnershipCompanyInsider OwnershipHLSHLS Therapeutics0.49%NXSNexus Gold0.51%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableHLSHLS Therapeutics9131.92 millionN/ANot OptionableNXSNexus GoldN/A41.87 millionN/ANot OptionableNXS, HLS, and EOF HeadlinesSourceHeadlineNexus Gold Announces Private Placementgoldseiten.de - April 12 at 5:26 PMNexus Gold Updates Dakouli 2 Gold Concession, Burkina Faso, West Africastockhouse.com - April 12 at 12:25 PMNexus War Civilization Codes (February 2024)twinfinite.net - March 29 at 9:39 PM'Stellaris Nexus' Is Now Called 'Nexus 5X' And Gets April Release Date - Trailerworthplaying.com - March 21 at 7:20 PMWeb3 Gaming Company Saltwater Raises $5.5M Seed Fundingmarkets.businessinsider.com - February 1 at 10:47 AMNexus Gold Provides Update on Public Listing of Nexus Metalsgoldseiten.de - January 30 at 5:12 PMNexus G1 Blackmagic box camera project creates controversyredsharknews.com - January 12 at 7:15 AMThe Nexus G1. A Box Camera Mod Using the Blackmagic Design Pocket 6K G1newsshooter.com - January 6 at 6:40 PMExcision Adds Nexus Tour Dates to Kia Forum — Here’s How To Get Presale Code Ticketsgrimygoods.com - December 13 at 7:37 PMNexus Gold Corp Class Amorningstar.com - December 7 at 8:17 PMNexus Gold and Belgravia Hartford Jointly Announce Revised Debt Settlement Transactionfinance.yahoo.com - November 22 at 6:31 PMClosing Bell: Nexus Gold Corp down on Monday (NXS)theglobeandmail.com - November 15 at 7:27 PMAll You Need To Know About ‘Nexus One’ Mobile App Launched By Navi Mumbai's Nexus Seawoods Mallmsn.com - November 6 at 8:50 AMHow Does Nexus Blitz Work In LOL?msn.com - October 30 at 3:50 AMClosing Bell: Nexus Gold Corp down on Thursday (NXS)theglobeandmail.com - October 20 at 8:46 PMClosing Bell: Nexus Gold Corp up on Friday (NXS)theglobeandmail.com - October 14 at 9:59 AMClosing Bell: Nexus Gold Corp up on Monday (NXS)theglobeandmail.com - October 3 at 1:24 AMBELGRAVIA HARTFORD Announces 13% Ownership in Nexus Gold and a 13% Ownership for Pennsylvania Hawthornefinance.yahoo.com - August 30 at 7:01 AMNexus Gold Announces Debt Settlementgoldseiten.de - August 28 at 8:26 PMClosing Bell: Nexus Gold Corp flat on Tuesday (NXS)theglobeandmail.com - August 3 at 6:32 PMClosing Bell: Nexus Gold Corp up on Thursday (NXS)theglobeandmail.com - August 3 at 6:32 PMClosing Bell: Nexus Gold Corp flat on Friday (NXS)theglobeandmail.com - July 15 at 9:06 AMNexus Gold Provides Update on Private Placementgoldseiten.de - June 30 at 6:50 PMNexus Gold Options Fofora Gold Project, Hounde Greenstone Belt, Burkina Fasojuniorminingnetwork.com - June 7 at 3:32 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsHLS TherapeuticsTSE:HLSHLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.Nexus GoldCVE:NXSNexus Gold Corp. engages in the exploration and evaluation of mineral properties in West Africa and Canada. The company explores for gold, silver, manganese, bauxite, copper, nickel, lead, zinc, and limestone/marble deposits. Its flagship property is the Bouboulou project located in Burkina Faso, West Africa. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.